BeOne Medicines’ (ONC) Buy Rating Reaffirmed at Truist Financial

Truist Financial restated their buy rating on shares of BeOne Medicines (NASDAQ:ONC) in a report published on Friday,Benzinga reports. They currently have a $448.00 price objective on the stock, up from their prior price objective of $420.00.

Several other research firms have also issued reports on ONC. Nomura upped their price objective on BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research note on Thursday, August 6th. Citizens Jmp upped their target price on BeOne Medicines from $405.00 to $463.00 and gave the company a “market outperform” rating in a research report on Friday. Citigroup reissued an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Wolfe Research reaffirmed an “outperform” rating and set a $370.00 price target on shares of BeOne Medicines in a research report on Monday, August 10th. Finally, Barclays lifted their price objective on shares of BeOne Medicines from $415.00 to $446.00 and gave the stock an “overweight” rating in a research note on Friday. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $434.79.

BeOne Medicines Trading Up 5.1%

BeOne Medicines stock traded up $19.71 during midday trading on Friday, hitting $406.96. 941,725 shares of the stock were exchanged, compared to its average volume of 364,122. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $410.71. The stock has a market capitalization of $44.68 billion, a PE ratio of 51.71 and a beta of 0.63. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $363.49 and a two-hundred day simple moving average of $326.34.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Equities research analysts anticipate that BeOne Medicines will post 8.99 EPS for the current fiscal year.

Insider Activity at BeOne Medicines

In related news, insider Xiaodong Wang sold 31,028 shares of the firm’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $362.97, for a total value of $11,262,233.16. Following the transaction, the insider owned 31,028 shares in the company, valued at approximately $11,262,233.16. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 54,892 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 376,373 shares of company stock worth $134,848,154 in the last quarter. 6.19% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently bought and sold shares of the company. Fisher Asset Management LLC acquired a new position in shares of BeOne Medicines in the 3rd quarter valued at approximately $367,000. Russell Investments Group Ltd. boosted its position in shares of BeOne Medicines by 34.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 29,621 shares of the company’s stock worth $10,839,000 after acquiring an additional 7,556 shares in the last quarter. Jefferies Financial Group Inc. boosted its position in shares of BeOne Medicines by 184.4% during the 3rd quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company’s stock worth $6,660,000 after acquiring an additional 11,800 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new position in BeOne Medicines in the third quarter valued at approximately $106,000. Finally, Allspring Global Investments Holdings LLC increased its stake in BeOne Medicines by 22.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company’s stock valued at $340,000 after acquiring an additional 178 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.